Roland Magnusson/iStock Editorial via Getty Images
AstraZeneca (AZN) posted stronger-than-expected Q3 results, fueled by continued strength in its oncology portfolio. The U.K. drugmaker reported adjusted EPS of $2.38, well above the $1.13 consensus, while revenue rose 11.9% year-over-year to $15.19B, topping estimates by $420M.
Oncology product sales
Pakistan’s Shehbaz Sharif government is preparing to table the 27th Constitutional Amendment in Parliament, a proposal that could give more...
When Ozempic and Wegovy launched, their bombshell success was only going to be exclusive to their maker—Novo Nordisk—for a matter...
Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking...
Bitcoin has been falling again — but unlike in last month’s selloff, it’s not leverage breaking the market.The original cryptocurrency...
Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking...
New York City Mayor-elect Zohran Mamdani swept to victory Tuesday evening on a platform of affordability, anchored by a plan...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
